Lawrence S. Lamb, PhD


Rank:
Professor Lamb_Larry

Division: Hematology & Oncology

Campus Address: WTI 510F

Phone: (205) 996-2335

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Departmental Affiliation(s):
Primary: Medicine
Secondary: Pediatrics
Secondary: Pathology

Research Description:
Dr. Lawrence Lamb is a Clinical Laboratory Immunologist and Professor of Medicine specializing in transplantation immunology. He also is cross-appointed as Professor of Pathology and Pediatrics and is boarded by the Oncology Nursing Certification Corporation for Advanced Practice in Oncology Nursing (AOCNS). Dr. Lamb directs the UAB Cell Therapy Laboratory and cGMP Cell Manufacturing Facility in the Section of Bone Marrow Transplant and Cellular Therapy. Dr. Lamb's group was the first to describe homeostatic reconstitution of gamma/delta T cells in patients who receive alpha/beta T cell depleted bone marrow grafts and an association between gamma/delta T cell recovery with disease-free survival in allogeneic bone marrow transplantation patients as well as gamma/delta T cell receptor CDR3 conservation in leukemia patients. He currently directs an independent research program for evaluation and translation of innate cell-based therapies for Glioblastoma Multiforme and has been funded by the NINDS (5R21NS57341), NCI (2 P50 CA097247), Elsa Pardee Foundation, Leukemia and Lymphoma Society. He also held the National Brain Tumor Society's Samuel Gershon Leadership Chair for Glioblastoma Research for 2008-2010. Dr. Lamb's laboratory anticipates the initial clinical trials for this therapy to initiate in late 2013.

Selected Publications:
Godder, K.T. et al. Long term disease-free survival in acute leukemia patients recovering with increased gamma/delta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39, 751-7 (2007).

Lamb, L.S., Jr. et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. Journal of Hematotherapy. 5, 503-9 (1996).

Lamb LS, Gee AP, Musk P, O'Hanlon TP, Hazlett LJ, Geier SS, Folk RS, Harris WG, McPherson K, Lee C, Henslee-Downey PJ Influence of T cell depletion method on circulating gd T cell reconstitution and potential role in the graft versus leukemia effect. Cytotherapy 1: 7-19 (1999)

Meeh, P.F. et al. Characterization of the gamma/delta T cell response to acute leukemia. Cancer Immunol Immunother 55, 1072-80 (2006).

Godder K, Henslee-Downey PJ, Mehta J, Park B, Chiang KY, Abhyankar S, Lamb LS Long term disease-free survival in acute leukemia patients with increased gd T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplantation 39: 751 – 757 (2007).

Bryant NL, Suarez-Cuervo C, Gillespie GY, Markert JM, Nabors LB. Meleth S, Lopez RD, Lamb LS Characterization and Immunotherapeutic Potential of γδ T Cells in Patients with Glioblastoma Neuro-Oncology (2009) in press

Bryant, NL, Gillespie GY, Lopez, RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Hanes H, Suarez-Cuervo, Lamb LS Preclinical Evaluation of ex vivo Expanded/Activated γδ T Cells for Immunotherapy of Glioblastoma Multiforme J Neuro-Oncology 101: 179 – 188 (2011)

Lamb LS, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, Spencer HT Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: A strategy for combining chemo- and immunotherapy PloS One December 2012